Cash runway through Q3 2026 creates urgent financing overhang. The SER-155 irEC data readout in coming weeks is the key binary catalyst — positive data could extend runway via partnership/licensing; negative data would accelerate distress. Monitor for equity offering, partnership announcement, or going concern disclosure in next 10-Q.
Price Chart
Executive Summary
Seres Therapeutics reported Q1 2026 net loss of $19.9M vs net income of $32.7M in Q1 2025 (which included a $50M Nestlé milestone payment). EPS of -$2.08 beat consensus of -$1.88 by 5.3%, but revenue was negligible at $358K (grant revenue only). Cash runway extends only through Q3 2026, and the company is actively seeking partnerships and financing to fund pipeline programs including SER-155 (Phase 2 ready) and SER-603 (IND-enabling).
Key Financial Metrics
Key Facts
- Q1 2026 net loss $19.9M vs net income $32.7M in Q1 2025 (which included $50M Nestlé milestone payment)
- EPS -$2.08 beat consensus -$1.88 by 5.3%
- Revenue $358K (grant revenue only) vs $0 consensus; no product revenue
- Cash and equivalents $29.8M as of March 31, 2026; expects to fund operations only through Q3 2026
- Operating expenses $21.3M, down ~$6M YoY due to completion of Nestlé transition services
- SER-155 Phase 2 ready for allo-HSCT but seeking funding to commence study
- Investigator-sponsored SER-155 study in irEC (15 patients enrolled) data expected in coming weeks
- SER-603 IND-enabling activities ongoing for IBD
- Going concern risk: cash runway only through Q3 2026 with no clear financing source
- Accumulated deficit $992.3M
Financial Impact
Net loss $19.9M; cash burn rate ~$5M/month; cash runway through Q3 2026 only
Risk Factors
- Cash runway only through Q3 2026 — going concern risk if no financing secured
- No product revenue; fully dependent on pipeline milestones and external funding
- SER-155 irEC study is small (n=15) — data may be inconclusive
- Potential dilutive equity offering to extend cash runway
- Nasdaq continued listing risk (market cap $74M, potential minimum bid price issues)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287503 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.98 | awaiting T+20 | — | $1.80 (+9.09%) |
Aug 24, 2026 9w ago | EFFECT | $4.66 $4.02 | ▲ +13.73% | ▲ +15.05% | $1.80 (+61.37%) |
Aug 5, 2026 11w ago | 8-K | $5.01 $5.54 | ▲ +10.69% | ▲ +11.29% | $1.80 (−64.04%) |
Jul 8, 2026 15w ago | 8-K | $7.14 $5.01 | ▼ −29.90% | ▼ −33.17% | $1.80 (−74.79%) |
Jun 5, 2026 20w ago | 8-K | $6.63 $7.71 | ▲ +16.29% | ▲ +14.43% | $1.80 (−72.85%) |
Jun 5, 2026 20w ago | Press Release | $6.63 $7.71 | ▲ +16.29% | ▲ +14.43% | $1.80 (−72.85%) |
May 19, 2026 23w ago | Insider Cluster | $7.66 $6.61 | ▼ −13.71% | ▼ −14.45% | $1.80 (−76.50%) |
May 5, 2026 25w ago | 8-K | $7.50 $7.33 | ▲ +2.27% | ▲ +7.22% | $1.80 (+76.00%) |
May 5, 2026 25w ago | Press Release | $7.50 $7.33 | ▲ +2.27% | ▲ +7.22% | $1.80 (+76.00%) |
May 4, 2026 25w ago | Press Release | $7.69 $7.64 | ▼ −0.65% | ▼ −6.30% | $1.80 (−76.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers